Interview with Charles Woler, CEO, Endotis Pharma
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
Address: 102 avenue Gaston Roussel
93230 Romainville France
Tel: +33 (0)1 48 46 43 91
Endotis Pharma is a biopharmaceutical company dedicated to the discovery and development of small-glyco drugs (SGDs, heparin / heparan sulphate mimetics) for use in thrombosis, oncology and a range of other indications with several potential blockbuster drugs. Founded in february 2003, Endotis is a privately held company which currently employs 34 people between sites in Paris and Lille.
Endotis’ business model is to develop antithrombotic drugs in man until proof-of principle (oral anticoagulants) or Phase IIb dose finding (parenteral antithrombotics), and then partner them; while in other therapeutic areas such as oncology, partnering could take place once proof of concept in animal is demonstrated.
Endotis has three main areas of activity:
– A derisked thrombosis franchise of heparin-derived synthetic oligosaccharides
– An oncology pipeline consisting of heparan sulfate mimetics
– A drug discovery engine: unique know-how from discovery to manufacturing of small-glyco drugs (SGDs) with range of applications
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
The US chooses to price its innovative drugs based on a market approach which is very different from the French system. Could you explain how the French model rewards innovative…
The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain…
What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that…
See our Cookie Privacy Policy Here
